KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Astrazeneca (AZN) Capital Leases (2018)

Historic Capital Leases for Astrazeneca (AZN) over the last 2 years, with Q4 2018 value amounting to $361.0.

Astrazeneca's Capital Leases changed N/A to $361.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $361.0, marking a year-over-year change of. This contributed to the annual value of $361.0 for FY2018, which is N/A changed from last year.
As of Q4 2018, Astrazeneca's Capital Leases stood at $361.0.
Astrazeneca's Capital Leases' 5-year high stood at $361.0 during Q4 2018, with a 5-year trough of $361.0 in Q4 2018.